JPWO2023278607A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023278607A5
JPWO2023278607A5 JP2023579696A JP2023579696A JPWO2023278607A5 JP WO2023278607 A5 JPWO2023278607 A5 JP WO2023278607A5 JP 2023579696 A JP2023579696 A JP 2023579696A JP 2023579696 A JP2023579696 A JP 2023579696A JP WO2023278607 A5 JPWO2023278607 A5 JP WO2023278607A5
Authority
JP
Japan
Prior art keywords
nucleotides
dsrna agent
antisense strand
strand
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528503A (ja
JP2024528503A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035561 external-priority patent/WO2023278607A1/en
Publication of JP2024528503A publication Critical patent/JP2024528503A/ja
Publication of JPWO2023278607A5 publication Critical patent/JPWO2023278607A5/ja
Publication of JP2024528503A5 publication Critical patent/JP2024528503A5/ja
Pending legal-status Critical Current

Links

JP2023579696A 2021-06-29 2022-06-29 ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法 Pending JP2024528503A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163216119P 2021-06-29 2021-06-29
US63/216,119 2021-06-29
US202263353953P 2022-06-21 2022-06-21
US63/353,953 2022-06-21
PCT/US2022/035561 WO2023278607A1 (en) 2021-06-29 2022-06-29 Leucine-rich repeat kinase 2 (lrrk2) irna agent compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024528503A JP2024528503A (ja) 2024-07-30
JPWO2023278607A5 true JPWO2023278607A5 (https=) 2025-07-07
JP2024528503A5 JP2024528503A5 (https=) 2025-07-07

Family

ID=84692073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579696A Pending JP2024528503A (ja) 2021-06-29 2022-06-29 ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法

Country Status (13)

Country Link
US (1) US20240301426A1 (https=)
EP (1) EP4363588A1 (https=)
JP (1) JP2024528503A (https=)
KR (1) KR20240033237A (https=)
AU (1) AU2022303358A1 (https=)
BR (1) BR112023027446A2 (https=)
CA (1) CA3225740A1 (https=)
CL (3) CL2023003984A1 (https=)
CO (1) CO2023018579A2 (https=)
IL (1) IL309548A (https=)
MX (1) MX2024000065A (https=)
TW (1) TW202317149A (https=)
WO (1) WO2023278607A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238385A2 (en) * 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
CN121712891A (zh) * 2023-06-20 2026-03-20 阿达尔克斯制药有限公司 Lrrk2调节组合物及其使用方法
AU2024353921A1 (en) 2023-09-27 2026-04-16 Neuro3 Therapeutics (Suzhou) Ltd. Novel sirna constructs, therapeutics, and modifications
CN120082552A (zh) * 2023-12-01 2025-06-03 艾码生物科技(南京)有限公司 初级-miRNA及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110205A1 (en) * 2013-01-11 2014-07-17 Children's Medical Center Corporation Methods and compositions for the production of sirnas
TWI833770B (zh) * 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Similar Documents

Publication Publication Date Title
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
JP2021518125A5 (https=)
JP2020534268A (ja) アンジオポエチン様3(ANGPTL3)の発現を阻害するためのRNAi剤および組成物、ならびに使用方法
JPWO2020132227A5 (https=)
US20250092403A1 (en) Compositions and methods for inhibiting ketohexokinase (khk)
WO2016149020A1 (en) Rna interference agents
TW202202153A (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
JP2025525898A (ja) アンジオテンシノーゲン(agt)を標的とする二重鎖rna及びその使用方法
IL294728A (en) lrrk2 RNA material preparations and methods of using them
CA3246175A1 (en) GLAUCOMA TREATMENT METHODS
TW202400193A (zh) 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
JPWO2021202511A5 (https=)
JPWO2021188795A5 (https=)
JPWO2023044094A5 (https=)
WO2023208109A1 (zh) 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途
JPWO2023278607A5 (https=)
US11634715B2 (en) Methods and compositions for treating bile duct paucity-associated conditions
JPWO2021222065A5 (https=)
WO2025040002A1 (zh) 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途
JPWO2023049871A5 (https=)
JPWO2022076291A5 (https=)
JPWO2021150969A5 (https=)
US20220186229A1 (en) Methods and compositions for inhibiting expression of cyp27a1
RU2024101876A (ru) АГЕНТ иРНК, ДЕЙСТВУЮЩИЙ НА КИНАЗУ 2 ОБОГАЩЕННОГО ЛЕЙЦИНОМ ПОВТОРА (LRRK2), СОДЕРЖАЩИЕ ЕГО КОМПОЗИЦИИ И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
US20260055414A1 (en) Compositions and methods for inhibiting xdh expression